Last reviewed · How we verify
NCT04311476
Autologous Cord Blood Cells for Prevention of BPD in Preterm
Phase 2 trial testing Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy in Safety Issues in 62 participants. Completed in 1 January 2020.
1 January 2020
Quick facts
| Lead sponsor | yangjie |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 62 |
| Start date | 1 July 2018 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy
- 0.9% Sodiun Chloride — full drug profile →
Conditions studied
- Safety Issues — all drugs for Safety Issues →
- BPD - Bronchopulmonary Dysplasia — all drugs for BPD - Bronchopulmonary Dysplasia →
- Neonatal Death — all drugs for Neonatal Death →
Sponsor
yangjie — full company profile →
Who can join
Adults 28 Weeks to 32 Weeks, any sex, with Safety Issues or BPD - Bronchopulmonary Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the effect of Autologous cord blood cells infusion on prevention of bronchopulmonary dysplasia in very preterm neonates
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Application of Umbilical Cord Blood for the Clinical Prevention and Treatment of Complications in Preterm Infants(Review).
Xu L, Shuzhe X, Jie Y. · · 2026 · PMID 41021185 · DOI 10.1007/s12015-025-10988-4
Verify or expand the search:
- PubMed search for NCT04311476
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Safety Issues
Currently open trials in the same condition.
- NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
- NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
Other yangjie trials
Trials by the same sponsor.
- NCT03855202 — The Treatment of Bronchopulmonary Dysplasia by Instillation PS and Mononuclaer Cells in Preterms · Phase 1 · unknown
- NCT04348799 — Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia · completed
- NCT03104946 — To Research the Relation Between Neonatal Morbidities and Poor Outcome in Preterm Infants · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04311476 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by yangjie
- Last refreshed: 2 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04311476.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing